MIT Koch Institute
November 20, 2019
Dragonfly, co-founded by KI director Tyler Jacks, launched its first clinical trial, a study of multiple solid tumor types, with a drug candidate called DF1001; the drug is the first from its TriNKET™ platform of NK cell-based immunotherapies to move into humans. The company also entered a partnership with AbbVie to help commercialize other candidates in its pipeline.